Pernix Therapeutics Holdings, Inc. (PTX) At $2.59 Forms Bottom; 3 Analysts Are Bullish Interface, Inc. (TILE) Last Week

January 15, 2018 - By Jerrie Dane

Pernix Therapeutics Holdings, Inc. (PTX) formed multiple bottom with $2.51 target or 3.00% below today’s $2.59 share price. Pernix Therapeutics Holdings, Inc. (PTX) has $30.50M valuation. The stock decreased 6.34% or $0.175 during the last trading session, reaching $2.585. About 229,867 shares traded or 59.73% up from the average. Pernix Therapeutics Holdings, Inc. (NASDAQ:PTX) has risen 9.00% since January 15, 2017 and is uptrending. It has underperformed by 7.70% the S&P500.

Among 7 analysts covering Interface (NASDAQ:TILE), 3 have Buy rating, 2 Sell and 2 Hold. Therefore 43% are positive. Interface had 12 analyst reports since July 31, 2015 according to SRatingsIntel. The company was initiated on Friday, November 4 by Seaport Global Securities. Nomura maintained the shares of TILE in report on Friday, October 27 with “Buy” rating. The rating was maintained by SunTrust on Thursday, October 26 with “Buy”. The firm has “Underweight” rating by Barclays Capital given on Thursday, April 7. The rating was upgraded by Stifel Nicolaus on Friday, October 30 to “Buy”. Stifel Nicolaus maintained it with “Hold” rating and $1900 target in Thursday, July 27 report. The stock of Interface, Inc. (NASDAQ:TILE) has “Underperform” rating given on Friday, June 24 by Raymond James. On Friday, December 16 the stock rating was initiated by Macquarie Research with “Neutral”. The stock of Interface, Inc. (NASDAQ:TILE) has “Equal-Weight” rating given on Thursday, February 25 by Barclays Capital. On Wednesday, April 27 the stock rating was downgraded by Stifel Nicolaus to “Hold”. See Interface, Inc. (NASDAQ:TILE) latest ratings:

27/10/2017 Broker: Nomura Rating: Buy Old Target: $24 New Target: $28 Maintain
26/10/2017 Broker: SunTrust Rating: Buy New Target: $25.0 Maintain
27/07/2017 Broker: Stifel Nicolaus Rating: Hold New Target: $19.0000 Maintain

Among 4 analysts covering Pernix Therapeutics (NASDAQ:PTX), 1 have Buy rating, 0 Sell and 3 Hold. Therefore 25% are positive. Pernix Therapeutics had 9 analyst reports since August 7, 2015 according to SRatingsIntel. The rating was downgraded by Oppenheimer to “Perform” on Thursday, March 17. The firm has “Strong Buy” rating by Needham given on Friday, August 7. The firm earned “Buy” rating on Friday, March 11 by Brean Capital. The company was downgraded on Friday, March 11 by Needham. The rating was reinitiated by JMP Securities on Wednesday, September 9 with “Market Outperform”. The stock has “Buy” rating by Brean Capital on Tuesday, February 9. As per Friday, August 12, the company rating was downgraded by Brean Capital. The company was maintained on Friday, August 7 by Brean Capital.

Since August 15, 2017, it had 0 buys, and 9 selling transactions for $2.12 million activity. Shares for $619,650 were sold by HENDRIX DANIEL T on Thursday, October 26. On Tuesday, September 5 the insider Nigel Stansfield sold $162,705. 29,500 shares were sold by KENNEDY CHRISTOPHER G, worth $646,640 on Friday, September 29.

Interface, Inc. designs, produces, and sells modular carpet products primarily in the Americas, Europe, and the Asia-Pacific. The company has market cap of $1.55 billion. It offers modular carpets under the Interface and FLOR brands; carpet tiles under the GlasBacRE brand name for use in commercial interiors, including offices, healthcare facilities, airports, educational and other institutions, hospitality spaces, and retail facilities, as well as residential interiors; modular resilient flooring products; and luxury vinyl tile products. It has a 30.45 P/E ratio. The firm also provides an adapted version of its carpet tile for the healthcare facilities market; and two-meter roll goods that are structure-backed for use in education, healthcare, and government markets, as well as carpet replacement, installation, and maintenance services.